Trending...
- Spokane: SPD Participates in a Statewide Motorcycle Safety Emphasis
- Aderra Opens in Magnolia, Texas, Offering a New Model for 62+ Homeownership
- Salestrics Releases Version 2.0 to Unify CRM, Business Email, and Operations on a Single Customer Graph
VANCOUVER, British Columbia - Washingtoner -- 2020-07-30: Scientists now have a better understanding into the aging process, giving us a better explanation of the cellular changes that lead our body and brain to decline as we age. Many believe that inflammation, stress, diet, exercise, and genetics greatly contribute to our aging process.
New studies are pointing to promising treatments that could slow, stop, or even reverse the signs of aging. This isn't just about turning back the clock in order to have a longer life span, it's about extending our healthy years.
In one study, mice were given pills that mimicked the positive benefits of exercise. If it works in mice would it be effective in humans? And what does this portend for the future, if our lifespan increases and we all live decades longer?
The business of anti-aging and rejuvenation is gaining steam and should be on the radar of investors — the Bank of America has forecasted that the market will balloon from $110 billion today, to nearly to $610 billion by 2025.
More on Washingtoner
Researchers have jumped on this trend too. In 2012, only 73 trials were conducted to reverse aging and that number doubled by the end of 2017 to 145. In 2018, this industry accounted for the most significant amount of investment, as market participants attracted an amount close to $800M (for comparison, back in 2014, it was only about $100M). The number of investment deals is also growing, with the highest number of the past six years recorded in 2017 (25 according to CB Insights, up from 13 a year earlier).
Companies like Juvenescence have raised over $100M to advance multiple anti-aging programs. Juvenescence believes that recent scientific and medical advances will enable the development of therapeutics that meaningfully improve human health and extends our lifespan.
Here are additional industry developments we're excited about:
Juvenescence's portfolio currently includes Insilico Medicine, a next-generation artificial intelligence company specializing in the application of deep learning to drug discovery and aging research. Juvenescence AI, a joint venture with Insilico Medicine focused on the clinical development of AI-generated compounds.
More on Washingtoner
UNITY Biotechnology, a company developing therapeutics to extend healthspan with an initial focus on cellular senescence..
AgeX Therapeutics, a company applying intellectual property related to cell immortality and pluripotency.
Finding the latest developments
Investors can follow the latest advancements in anti-aging and rejuvenation by reading magazines such as Nature and The New Scientist. Both publications recently featured interesting articles that highlighted recent developments. We also recommend following websites like fiercebiotech, (https://www.fiercebiotech.com/) scientificamerican (https://www.scientificamerican.com/), and tracking IPOs (https://www.nasdaq.com/market-activity/ipos) to find other companies developing innovative technologies
New studies are pointing to promising treatments that could slow, stop, or even reverse the signs of aging. This isn't just about turning back the clock in order to have a longer life span, it's about extending our healthy years.
In one study, mice were given pills that mimicked the positive benefits of exercise. If it works in mice would it be effective in humans? And what does this portend for the future, if our lifespan increases and we all live decades longer?
The business of anti-aging and rejuvenation is gaining steam and should be on the radar of investors — the Bank of America has forecasted that the market will balloon from $110 billion today, to nearly to $610 billion by 2025.
More on Washingtoner
- Spokane: Mayor Brown Launches Data Center Work Group Following Adoption of One-Year Moratorium
- Spokane City Council Passes Renters Right to Cooling Ordinance
- Salestrics Introduces PraiseEngine: The AI-Native Review Engine Built to Fix Social Proof
- K2 Integrity Names Michael Kallabat Global Head of Investigations and Disputes
- Socialhose Eyes Southeast Asia and Rejects the Copy-Paste Expansion Playbook
Researchers have jumped on this trend too. In 2012, only 73 trials were conducted to reverse aging and that number doubled by the end of 2017 to 145. In 2018, this industry accounted for the most significant amount of investment, as market participants attracted an amount close to $800M (for comparison, back in 2014, it was only about $100M). The number of investment deals is also growing, with the highest number of the past six years recorded in 2017 (25 according to CB Insights, up from 13 a year earlier).
Companies like Juvenescence have raised over $100M to advance multiple anti-aging programs. Juvenescence believes that recent scientific and medical advances will enable the development of therapeutics that meaningfully improve human health and extends our lifespan.
Here are additional industry developments we're excited about:
Juvenescence's portfolio currently includes Insilico Medicine, a next-generation artificial intelligence company specializing in the application of deep learning to drug discovery and aging research. Juvenescence AI, a joint venture with Insilico Medicine focused on the clinical development of AI-generated compounds.
More on Washingtoner
- $40 Billion Global Market Value by 2030 Projected in Unmanned Aerial Vehicle or Other Drone Technology Sector, Growing at 9.2% Compound Annual Growth
- Tacoma City Council Expresses Opposition to Initiative Measure No. IL26-001 and Initiative Measure No. IL26-638
- As the FCC Router Ban Creates a National Supply Chain Crisis, Haawke Hash Offers the Infrastructure
- Spokane: Second-Alarm Brush Fire Contained at People's Park
- $620 Million in Recent Government Contract Awards with More Than $1.2 Billion in Annualized Revenue: Circle8 Group (N A S D A Q: CIRC)
UNITY Biotechnology, a company developing therapeutics to extend healthspan with an initial focus on cellular senescence..
AgeX Therapeutics, a company applying intellectual property related to cell immortality and pluripotency.
Finding the latest developments
Investors can follow the latest advancements in anti-aging and rejuvenation by reading magazines such as Nature and The New Scientist. Both publications recently featured interesting articles that highlighted recent developments. We also recommend following websites like fiercebiotech, (https://www.fiercebiotech.com/) scientificamerican (https://www.scientificamerican.com/), and tracking IPOs (https://www.nasdaq.com/market-activity/ipos) to find other companies developing innovative technologies
Source: Braeden William Sinclair Lichti
0 Comments
Latest on Washingtoner
- The truth behind mylifesflow.com and the poet, Taryn "My Life's Flow" Robinson
- 91 Per Cent of Enterprises Will Increase AI Spending. Most Can't See the Cost — or the Risk!
- New ProEssentials v11: Native WinUI Charting Library, 100M Points in 15ms, Following Microsoft's Vision for True Native Swap-Chain Rendering
- Salestrics Releases Version 2.0 to Unify CRM, Business Email, and Operations on a Single Customer Graph
- Aderra Opens in Magnolia, Texas, Offering a New Model for 62+ Homeownership
- Spokane: SPD Participates in a Statewide Motorcycle Safety Emphasis
- What's New in Hokkaido, Autumn 2026
- Tacoma: Homicide Investigation – 400 Block of East 75th Street
- Are "Buck Teeth" Hereditary? Spokane Valley Dentist Explains Children's Smile Development
- CRG Awarded NASA SEWP VI Contracts in Categories B and C
- Spokane: Council Member Zappone Awarded Certificate of Municipal Leadership
- Heidi G. Villari of The Villari Firm, PLLC Named to Super Lawyers for the Tenth Consecutive Year
- Spokane: SPD Assists Stevens County Sheriff's Office Locate a Reckless Vehicle
- Elevate Your Sneakers With Crep Protect Trek Laces
- Meet Privateer: Tucson's High-Tech Security Force Built With Paramilitary Precision
- James Richey, CEO of JouleFit, to Be Featured on the July Edition of the Longevity Leaders Project
- Dynamic Dachshund Dog Goes Global: Remember Point Launches a New Bilingual Children's Book
- DARPA Selects NRx Pharmaceuticals Defense Subsidiary for Contract Negotiations on FDA-Authorized SPARC-TMS Clinical Trial Advancing Mental Health Care
- The Great Junk Hunt is Coming Home
- From the Racetrack to the Boardroom: Aston Martin and Aramco Formula One Partnership Accelerates Circle8 Group: (N A S D A Q: CIRC)